[조사자료] 글로벌 클로르페니라민 말레산염 시장 (2023-2032) : 정제, 시럽, 점안제

■ 영문 제목 : Chlorpheniramine Maleate Market By Dosage Form (Tablets, Syrup, Eye Drops), By Application (Allergy, Hay Fever (Allergic Rhinitis), Common Cold, Watery Eyes, Itchy Throat/Skin, Anaphylactic Shock, Urticaria), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032
	■ 상품코드 : ALD23SEP111 ■ 조사/발행회사 : Allied Market Research ■ 발행일 : 2023년 4월 ■ 페이지수 : 438 ■ 작성언어 : 영어 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 ■ 조사대상 지역 : 세계

■ 판매가격 / 옵션 (부가세 10% 별도)

Single User	USD5,730 ⇒환산￦7,735,500	견적의뢰/주문/질문
5 User	USD6,450 ⇒환산￦8,707,500	견적의뢰/주문/질문
Enterprise User	USD9,600 ⇒환산￦12,960,000	견적의뢰/구입/질문

※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.

세계의 클로르페니라민 말레산염 시장 규모는 2022년에 4억 6,860만 달러로 평가되었으며, 2023년부터 2032년까지 연평균 4.9%씩 성장하여 2032년에는 7억 5,140만 달러에 달할 것으로 예상됩니다.클로르페니라민은 알레르기, 건초열, 감기 증상을 완화하는 데 사용되는 항히스타민제입니다. 이러한 증상에는 발진, 눈곱, 눈/코/목/피부 가려움증, 기침, 콧물, 재채기 등이 있습니다. 이 약은 알레르기 반응 중에 신체가 생성하는 특정 천연 물질(히스타민)을 차단하는 방식으로 작용합니다. 신체에서 생성되는 또 다른 천연 물질(아세틸콜린)을 차단함으로써 체액을 건조시켜 눈곱, 콧물 등의 증상을 완화하는 데 도움을 줍니다.

클로르페니라민 말레산염 시장의 성장을 이끄는 주요 요인은 알레르기 및 알레르기 비염, 두드러기와 같은 관련 호흡기 질환의 유병률 증가입니다. 예를 들어, 미국 천식 및 알레르기 재단이 2021년에 발표한 보고서에 따르면 미국에서는 약 8,100만 명이 계절성 알레르기 비염(건초열) 진단을 받았습니다. 이는 성인의 약 26%(6,700만 명), 어린이의 19%(1,400만 명)에 해당하는 수치입니다. 또한 제약 기술 및 약물 전달 시스템의 발전으로 인해 서방형 정제 또는 액체 제제와 같은 새로운 제형의 클로르페니라민 말레산염가 개발되어 예측 기간 동안 시장의 성장을 주도 할 것으로 예상되는 개선 된 효능, 편의성 및 환자 순응도를 제공합니다.

그러나 자연 요법, 전체 론적 접근 방식 또는 다른 유형의 약물에 대한 선호도와 같은 소비자 선호도의 변화와 졸음, 구강 건조, 시력 저하 및 요실금과 같은 클로르페니라민 말레산염의 잠재적 부작용은 시장 성장을 방해합니다. 반대로, 부작용이 적고 효능이 더 큰 새로운 치료법 개발을위한 R&D 활동의 급증은 예측 기간 동안 시장 성장을위한 수익성있는 기회를 제공 할 것으로 예상됩니다.
클로르페니라민 말레산염 시장은 제형, 응용 분야, 최종 용도 및 지역으로 분류됩니다. 제형에 따라 시장은 정제, 시럽 및 점안액으로 분류됩니다. 용도별로는 알레르기, 건초열(알레르기 비염), 감기, 눈곱, 인후/피부 가려움증, 아나필락시스 쇼크, 두드러기 등으로 세분화되어 있습니다. 유통 채널별로 시장은 병원 약국, 소매 약국 및 온라인 약국으로 분류됩니다. 지역별로 시장은 북미, 유럽, 아시아 태평양 및 중남미/중동/아프리카로 분석됩니다.

북미는 2022년 클로르페니라민 말레산염 시장에서 최대 점유율을 차지했으며 예측 기간 동안 지배적인 위치를 유지할 것으로 예상됩니다. 이는 알레르기 질환의 유병률 증가, 성인이 알레르기 발병 위험이 더 높을 수 있으므로 노인 인구의 증가, 건초열, 감기, 아나필락시스 쇼크 등과 같은 알레르기 질환 치료에 사용되는 약물에 대한 높은 의료비 지출에 기인합니다. 또한 알레르기의 증상 및 관리에 대한 인구의 인식이 급증하고 의료 인프라가 발전함에 따라 시장 성장이 촉진 될 것으로 예상됩니다.

아시아 태평양 지역은 알레르기 질환의 발생률 증가와 인구 및 도시화의 급증으로 인해 예측 기간 동안 가장 빠른 CAGR을 기록 할 것으로 예상됩니다. 또한 의료 인프라의 성장과 알레르기 비염, 두드러기 및 건초열과 같은 알레르기 질환을 치료하기위한 신약 개발을위한 주요 시장 참여자의 R&D 활동이 급증하면서 시장의 성장이 촉진됩니다.
클로르페니라민 말레산염 시장에서 활동하는 주요 업체는 Alkeem Laboratories Ltd., Bayer AG, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novalab Healthcare Pvt. Ltd., Capellon Pharmaceuticals, Sun Pharmaceutical Industries Limited, Viatris Inc., and Zydus Lifesciences Limited. 등이 있습니다.

이해 관계자를 위한 주요 이점
이 보고서는 2022년부터 2032년까지 클로르페니라민 말레산염 시장 분석의 시장 부문, 현재 동향, 추정치 및 역학에 대한 정량적 분석을 제공하여 일반적인 클로르페니라민 말레산염 시장 기회를 식별합니다.
시장 조사는 주요 동인, 구속 및 기회와 관련된 정보와 함께 제공됩니다.
포터의 다섯 가지 경쟁 요인 분석은 이해 관계자가 이익 지향적인 비즈니스 결정을 내리고 공급 업체-구매자 네트워크를 강화할 수 있도록 구매자와 공급 업체의 힘을 강조합니다.
클로르페니라민 말레산염 시장 세분화에 대한 심층 분석은 지배적인 시장 기회를 결정하는 데 도움이 됩니다.
각 지역의 주요 국가는 글로벌 시장에 대한 수익 기여도에 따라 매핑됩니다.
시장 플레이어 포지셔닝은 벤치마킹을 용이하게하고 시장 플레이어의 현재 위치에 대한 명확한 이해를 제공합니다.
이 보고서에는 지역 및 세계의 클로르페니라민 말레산염 시장 동향, 주요 업체, 시장 부문, 응용 분야 및 시장 성장 전략에 대한 분석이 포함되어 있습니다.

주요 시장 부문
제형별
정제
시럽
안약 점안액

용도별
알레르기
꽃가루 알레르기(알레르기 비염)
감기
눈곱
목/피부 가려움증
아나필락시스 쇼크
두드러기

유통 채널별
병원 약국
소매 약국
온라인 약국

지역별
북미
미국
캐나다
멕시코
유럽
독일
프랑스
영국
이탈리아
스페인
기타 유럽 지역
아시아 태평양
일본
중국
호주
인도
한국
기타 아시아 태평양 지역
중남미/중동/아프리카
브라질
사우디 아라비아
남아프리카 공화국
기타 중동 및 아프리카 지역

주요 기업
○ Alkem Laboratories Ltd.
○ Bayer AG
○ Capellon Pharmaceuticals
○ GlaxoSmithKline plc
○ Johnson & Johnson
○ Merck & Co., Inc.
○ Novalab Healthcare Pvt. Ltd.
○ Sun Pharmaceutical Industries Limited
○ Viatris Inc.
○ Zydus Lifesciences Limited

■ 보고서 개요

CHAPTER 1 : 소개
CHAPTER 2 : 개요
CHAPTER 3 : 시장 동향
CHAPTER 4 : 클로르페닐라민 말레인산염 시장, 제형별
CHAPTER 5 : 클로르페닐라민 말레인산염 시장, 용도별
CHAPTER 6 : 클로르페닐라민 말레인산염 시장, 유통 채널별
CHAPTER 7 : 클로르페닐라민 말레인산염 시장, 지역별
CHAPTER 8 : 경쟁 현황
CHAPTER 9 : 기업 정보

■ 보고서 목차

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Surge in technological advancement
3.4.1.2. Increase in urbanization and change in lifestyles
3.4.1.3. Increase in the prevalence of allergic conditions

3.4.2. Restraints
3.4.2.1. Potential side effects of chlorpheniramine maleate
3.4.2.2. Increase in shift towards alternative medicines

3.4.3. Opportunities
3.4.3.1. High growth potential in developing economies

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM
4.1. Overview
4.1.1. Market size and forecast
4.2. Tablets
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Syrup
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Eye Drops
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Allergy
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Hay Fever (Allergic Rhinitis)
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Common Cold
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Watery Eyes
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Itchy Throat/Skin
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
5.7. Anaphylactic Shock
5.7.1. Key market trends, growth factors and opportunities
5.7.2. Market size and forecast, by region
5.7.3. Market share analysis by country
5.8. Urticaria
5.8.1. Key market trends, growth factors and opportunities
5.8.2. Market size and forecast, by region
5.8.3. Market share analysis by country
CHAPTER 6: CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Retail Pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online Pharmacies
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: CHLORPHENIRAMINE MALEATE MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Dosage Form
7.2.3. Market size and forecast, by Application
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Dosage Form
7.2.5.1.3. Market size and forecast, by Application
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Dosage Form
7.2.5.2.3. Market size and forecast, by Application
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Dosage Form
7.2.5.3.3. Market size and forecast, by Application
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Dosage Form
7.3.3. Market size and forecast, by Application
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Dosage Form
7.3.5.1.3. Market size and forecast, by Application
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Dosage Form
7.3.5.2.3. Market size and forecast, by Application
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Dosage Form
7.3.5.3.3. Market size and forecast, by Application
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Dosage Form
7.3.5.4.3. Market size and forecast, by Application
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Dosage Form
7.3.5.5.3. Market size and forecast, by Application
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Dosage Form
7.3.5.6.3. Market size and forecast, by Application
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Dosage Form
7.4.3. Market size and forecast, by Application
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Dosage Form
7.4.5.1.3. Market size and forecast, by Application
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Dosage Form
7.4.5.2.3. Market size and forecast, by Application
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. Australia
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Dosage Form
7.4.5.3.3. Market size and forecast, by Application
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. India
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Dosage Form
7.4.5.4.3. Market size and forecast, by Application
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Dosage Form
7.4.5.5.3. Market size and forecast, by Application
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Dosage Form
7.4.5.6.3. Market size and forecast, by Application
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Dosage Form
7.5.3. Market size and forecast, by Application
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Dosage Form
7.5.5.1.3. Market size and forecast, by Application
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Dosage Form
7.5.5.2.3. Market size and forecast, by Application
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Dosage Form
7.5.5.3.3. Market size and forecast, by Application
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Dosage Form
7.5.5.4.3. Market size and forecast, by Application
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. GlaxoSmithKline plc
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Bayer AG
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Merck & Co., Inc.
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Johnson & Johnson
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Alkem Laboratories Ltd.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Viatris Inc.
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Zydus Lifesciences Limited
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Sun Pharmaceutical Industries Limited
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Novalab Healthcare Pvt. Ltd.
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.10. Capellon Pharmaceuticals
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio

LIST OF TABLES
TABLE 01. GLOBAL CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 02. CHLORPHENIRAMINE MALEATE MARKET FOR TABLETS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. CHLORPHENIRAMINE MALEATE MARKET FOR SYRUP, BY REGION, 2022-2032 ($MILLION)
TABLE 04. CHLORPHENIRAMINE MALEATE MARKET FOR EYE DROPS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 06. CHLORPHENIRAMINE MALEATE MARKET FOR ALLERGY, BY REGION, 2022-2032 ($MILLION)
TABLE 07. CHLORPHENIRAMINE MALEATE MARKET FOR HAY FEVER (ALLERGIC RHINITIS), BY REGION, 2022-2032 ($MILLION)
TABLE 08. CHLORPHENIRAMINE MALEATE MARKET FOR COMMON COLD, BY REGION, 2022-2032 ($MILLION)
TABLE 09. CHLORPHENIRAMINE MALEATE MARKET FOR WATERY EYES, BY REGION, 2022-2032 ($MILLION)
TABLE 10. CHLORPHENIRAMINE MALEATE MARKET FOR ITCHY THROAT/SKIN, BY REGION, 2022-2032 ($MILLION)
TABLE 11. CHLORPHENIRAMINE MALEATE MARKET FOR ANAPHYLACTIC SHOCK, BY REGION, 2022-2032 ($MILLION)
TABLE 12. CHLORPHENIRAMINE MALEATE MARKET FOR URTICARIA, BY REGION, 2022-2032 ($MILLION)
TABLE 13. GLOBAL CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 14. CHLORPHENIRAMINE MALEATE MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 15. CHLORPHENIRAMINE MALEATE MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 16. CHLORPHENIRAMINE MALEATE MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 17. CHLORPHENIRAMINE MALEATE MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 21. NORTH AMERICA CHLORPHENIRAMINE MALEATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 22. U.S. CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 23. U.S. CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 24. U.S. CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 25. CANADA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 26. CANADA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 27. CANADA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 28. MEXICO CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 29. MEXICO CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 30. MEXICO CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 31. EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 32. EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 33. EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 34. EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 35. GERMANY CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 36. GERMANY CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 37. GERMANY CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 38. FRANCE CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 39. FRANCE CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 40. FRANCE CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 41. UK CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 42. UK CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 43. UK CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 44. ITALY CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 45. ITALY CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 46. ITALY CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 47. SPAIN CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 48. SPAIN CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 49. SPAIN CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 50. REST OF EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 51. REST OF EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 52. REST OF EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 53. ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 54. ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 55. ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 56. ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 57. JAPAN CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 58. JAPAN CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 59. JAPAN CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 60. CHINA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 61. CHINA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 62. CHINA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 63. AUSTRALIA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 64. AUSTRALIA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 65. AUSTRALIA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 66. INDIA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 67. INDIA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 68. INDIA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 69. SOUTH KOREA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 70. SOUTH KOREA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 71. SOUTH KOREA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 73. REST OF ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 74. REST OF ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 75. LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 76. LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 77. LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 78. LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 79. BRAZIL CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 80. BRAZIL CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 81. BRAZIL CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 82. SAUDI ARABIA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 83. SAUDI ARABIA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 84. SAUDI ARABIA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 85. SOUTH AFRICA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 86. SOUTH AFRICA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 87. SOUTH AFRICA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 88. REST OF LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 89. REST OF LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 90. REST OF LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 91. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
TABLE 92. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 93. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
TABLE 94. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 95. BAYER AG: KEY EXECUTIVES
TABLE 96. BAYER AG: COMPANY SNAPSHOT
TABLE 97. BAYER AG: PRODUCT SEGMENTS
TABLE 98. BAYER AG: PRODUCT PORTFOLIO
TABLE 99. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 100. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 101. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 102. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 103. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 104. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 105. JOHNSON & JOHNSON: PRODUCT SEGMENTS
TABLE 106. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 107. ALKEM LABORATORIES LTD.: KEY EXECUTIVES
TABLE 108. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 109. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS
TABLE 110. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 111. VIATRIS INC.: KEY EXECUTIVES
TABLE 112. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 113. VIATRIS INC.: PRODUCT SEGMENTS
TABLE 114. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 115. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
TABLE 116. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
TABLE 117. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
TABLE 118. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
TABLE 119. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
TABLE 120. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 121. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
TABLE 122. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 123. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
TABLE 124. NOVALAB HEALTHCARE PVT. LTD.: KEY EXECUTIVES
TABLE 125. NOVALAB HEALTHCARE PVT. LTD.: COMPANY SNAPSHOT
TABLE 126. NOVALAB HEALTHCARE PVT. LTD.: PRODUCT SEGMENTS
TABLE 127. NOVALAB HEALTHCARE PVT. LTD.: PRODUCT PORTFOLIO
TABLE 128. CAPELLON PHARMACEUTICALS: KEY EXECUTIVES
TABLE 129. CAPELLON PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 130. CAPELLON PHARMACEUTICALS: PRODUCT SEGMENTS
TABLE 131. CAPELLON PHARMACEUTICALS: PRODUCT PORTFOLIO

※본 조사보고서 [글로벌 클로르페니라민 말레산염 시장 (2023-2032) : 정제, 시럽, 점안제] (코드 : ALD23SEP111) 판매에 관한 면책사항을 반드시 확인하세요.

※본 조사보고서 [글로벌 클로르페니라민 말레산염 시장 (2023-2032) : 정제, 시럽, 점안제] 에 대해서 E메일 문의는 여기를 클릭하세요.

※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!

[이하, 관련 보고서 소개]

글로벌 유기농 농약 시장 (2023-2032) : 생물 의학, 미생물, 식물, 광물
ALD23SEP213 / Allied Market Research / 2023년 6월 / 글로벌 유기농 농약 시장은 2022년 30억 달러 규모였으며 2023년부터 2032년까지 9.7%의 연평균 성장률을 보이며 2032년에는 76억 달러에 달할 것으로 예상됩니다.생물 살충제라고도 하는 유기농 살충제는 농업 및 원예 분야에서 곤충, 잡초,...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 유기농 농약 시장, 제품 유형별 CHAPTER 5 : 유기농 농약 시장, 유형별 CHAPTER 6 : 유기농 농약 시장, 형태별 CHAPTER 7 : 유기농 농약 시장, 용도별 CHAPTER 8 : 유기농 농약 시장, 지역별 CHAPTER...

글로벌 연기 및 방화 댐퍼 시장 (2023-2032) : 수동, 전동
ALD23SEP060 / Allied Market Research / 2023년 6월 / 글로벌 연기 및 방화 댐퍼 시장은 2022년에 1억 6,320만 달러로 평가되었으며, 2023년부터 2032년까지 5.5%의 연평균 성장률을 기록하면서 2032년에는 2억 7,760만 달러에 달할 것으로 예상됩니다. 연기 및 방화 댐퍼는 난방, 환기...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 연기 및 방화 댐퍼 시장, 유형별 CHAPTER 5 : 연기 및 방화 댐퍼 시장, 유통 채널별 CHAPTER 6 : 연기 및 방화 댐퍼 시장, 용도별 CHAPTER 7 : 연기 및 방화 댐퍼 시장, 지역별...

글로벌 제네릭 의약품 시장 (2023-2032) : 심혈관, 감염, 암, 당뇨병, 기타
ALD23SEP154 / Allied Market Research / 2023년 6월 / 글로벌 제네릭 의약품 시장은 2022년에 385,320,00백만 달러로 평가되었으며 2032년에는 835,706,50백만 달러에 달할 것으로 예상되며, 2023년부터 2032년까지 8.1%의 연평균 성장률을 보일 것으로 전망됩니다.제네릭 의약품은 용량 형태, 효능, 투여 방식, 품질, 성능...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 제네릭 의약품 시장, 치료 용도별 CHAPTER 5 : 제네릭 의약품 시장, 투여 경로별 CHAPTER 6 : 제네릭 의약품 시장, 유통 채널별 CHAPTER 7 : 제네릭 의약품 시장, 지역별 CHAPTER 8 : 경쟁 현황 CHAPTER...

글로벌 씬 클라이언트 시장 (2023-2032) : 독립형, 모니터 포함, 이동식
ALD23SEP266 / Allied Market Research / 2023년 6월 / 글로벌 씬 클라이언트 시장은 2022년에 16억 2,310만 달러로 평가되었으며, 2023년부터 2032년까지 4.8%의 연평균 성장률을 기록하면서 2032년에는 25억 7,065만 달러에 달할 것으로 예상됩니다. 글로벌 씬 클라이언트 시장은 린 클라이언트라고도 하는 씬...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 씬 클라이언트 시장, 폼팩터별 CHAPTER 5 : 씬 클라이언트 시장, 용도별 CHAPTER 6 : 씬 클라이언트 시장, 지역별 CHAPTER 7 : 경쟁 현황 CHAPTER 8 : 기업 정보...

글로벌 폴리에스테르 섬유 시장 (2023-2032) : 중실, 중공
ALD23SEP186 / Allied Market Research / 2023년 4월 / 글로벌 폴리에스테르 섬유 시장은 2022년 811억 달러 규모였으며, 2023년부터 2032년까지 연평균 7.1% 성장하여 2032년에는 1,601억 달러에 달할 것으로 예상됩니다.폴리에스테르 섬유는 산과 알코올의 화학 반응을 통해 생산되는 장쇄 합성 폴리머입니다. 폴리에스테르...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 폴리에스테르 섬유 시장, 형태별 CHAPTER 5 : 폴리에스테르 섬유 시장, 등급별 CHAPTER 6 : 폴리에스테르 섬유 시장, 제품 유형별 CHAPTER 7 : 폴리에스테르 섬유 시장, 용도별 CHAPTER 8 : 폴리에스테르 섬유 시장, 지역별 CHAPTER...